Stoke Therapeutics: A High-Stakes Bet on RNA to Redefine Dravet Syndrome

BEDFORD, MA – September 02, 2026

Next week, when executives from Stoke Therapeutics take the stage at the Cantor Global Healthcare Conference, their presentation will represent more than a routine corporate update. For investors, it's a critical look into a company with a strong analyst consensus but mounting R&D costs. For the medical community, it’s a progress report on what could be the first-ever disease-modifying treatment for Dravet syndrome, a devastating form of childhood epilepsy. And for the world of biotechnology, it is another test of the revolutionary power of RNA medicine.

Stoke announced that CEO Ian F. Smith and Chief Patient Officer Jason Hoitt will present on September 9th, placing a spotlight on its lead investigational medicine, zorevunersen. With enrollment for its pivotal Phase 3 study now complete and a rolling FDA submission on the horizon, the company is at an inflection point. The stakes are immense, but so is the potential reward: a chance to fundamentally alter the course of a brutal genetic disease and validate a platform technology with implications far beyond a single illness.

The Financial Tightrope: Cash Burn vs. Market Potential

For investors tracking Stoke (Nasdaq: STOK), the story is one of calculated, high-stakes investment. The company's Q2 2026 financial report painted a familiar picture for a late-stage biotech: revenue, primarily from collaborations with Biogen and Acadia, was down year-over-year, while expenses soared. Research and development costs nearly doubled to $49.5 million for the quarter, a direct result of advancing the global Phase 3 EMPEROR study for zorevunersen.

This aggressive spending has led to a net loss of $61.6 million for the quarter. Yet, Wall Street remains bullish. An overwhelming majority of analysts maintain a "Strong Buy" rating, with an average price target of $46.46—a significant premium over its current trading price. This optimism is rooted in two key factors: a robust cash position and the sheer market potential of zorevunersen.

Thanks to a recent at-the-market stock offering, Stoke's pro forma cash reserves stand at a healthy $420 million. Management asserts this runway is sufficient to fund operations through the potential U.S. launch of zorevunersen in early 2028. This financial stability is crucial as the company navigates the costly final stages of clinical development and prepares for commercialization.

Furthermore, the strategic collaboration with pharmaceutical giant Biogen serves as both a financial backstop and a powerful vote of confidence. While Stoke retains commercial rights in North America, Biogen is poised to handle commercialization across the rest of the world. This partnership not only de-risks the global launch but validates the science behind Stoke’s platform, providing investors with a clear path to a global market.

"The Biogen deal is a critical piece of the puzzle," noted one biotech analyst. "It allows Stoke to focus its resources on a successful U.S. launch while leveraging Biogen's global muscle. It’s a smart structure that maximizes the potential of the asset."

A New Hope for Dravet Syndrome

Beyond the balance sheets and stock charts lies the profound human impact of Stoke's work. Dravet syndrome is a severe, lifelong epileptic encephalopathy caused by a mutation in the SCN1A gene, leading to a ~50% reduction in a critical protein, NaV1.1. This deficiency triggers frequent, debilitating seizures and profound neurodevelopmental, cognitive, and behavioral impairments. Existing treatments, such as Epidiolex and Fintepla, are anti-seizure medications that manage symptoms but do not address the underlying genetic root cause.

This is where zorevunersen represents a paradigm shift. It is not another anti-seizure medication; it is designed to be a disease-modifying therapy. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform, zorevunersen is an antisense oligonucleotide (ASO) that binds to the RNA transcribed from the healthy, unaffected copy of the SCN1A gene. This action prevents non-productive splicing, thereby boosting the output of functional NaV1.1 protein. In essence, it aims to restore what the genetic mutation took away.

Recent data has bolstered hopes that this novel mechanism translates into real-world benefits. Just this week, Stoke and Biogen presented four-year data from the open-label extension (OLE) of their Phase 1/2a studies. The results showed "substantial, durable reductions in seizures" on top of standard-of-care treatments, supporting the drug's potential for long-term, disease-modifying effects. Having this data published in prestigious outlets like The New England Journal of Medicine has already raised significant awareness among neurologists.

With enrollment for the 162-patient Phase 3 EMPEROR study completed in June, all eyes are now on the final data readout expected in the third quarter of 2027. This data will form the cornerstone of a rolling New Drug Application (NDA) to the FDA, which Stoke plans to initiate in early 2027. The drug has already received Breakthrough Therapy, Rare Pediatric Disease, and Orphan Drug designations, smoothing its regulatory path forward.

Beyond Dravet: The Power of the TANGO Platform

While zorevunersen is the company's immediate focus, its success would carry far broader implications for the future of genetic medicine. The TANGO platform is not limited to Dravet syndrome. It is a technology designed to address a wide range of diseases caused by haploinsufficiency—a condition where a single functional copy of a gene is insufficient to produce the protein levels needed for normal health.

Stoke’s initial strategy targets diseases of the central nervous system and the eye, but the company has already stated that proof of concept has been demonstrated in other organs and systems. This opens the door to a future pipeline of therapies for dozens of other monogenic diseases that currently have no cure. Each disease represents a distinct patient population, but the underlying scientific approach—upregulating protein from a healthy gene—remains the same.

This platform potential is the long-term value proposition that excites strategists and scientists. It represents a move away from merely managing symptoms and toward correcting genetic deficits at the RNA level. As Stoke prepares for its presentation, the company carries the hopes of patients, the expectations of investors, and a technology that could help write the next chapter in RNA medicine.